{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.1","upperLimit":"82.7","value":"74.2"},{"groupId":"OG001","lowerLimit":"32.9","upperLimit":"61.5","value":"47.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"The reduction of bone scan lesion area (BSLA) by \\> 30% was used as the quantitative measure of BSR. BSR was a primary outcome measure for only the NRE CRPC Cohorts.","dispersionType":"95% Confidence Interval","groups":[{"description":"cabozantinib, 100 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.","id":"OG000","title":"NRE Cohort - CRPC 100 mg"},{"description":"cabozantinib, 39.4 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.","id":"OG001","title":"NRE Cohort - CRPC 39.4 mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From initial dose through final study visit up to 15 months","title":"Bone Scan Response (BSR) - NRE, CRPC","type":"PRIMARY","unitOfMeasure":"percentage of participants"}